Georgiamune
5 known investors
Georgiamune develops targeted immunomodulator drugs designed to regulate immune signaling pathways for treating cancer and autoimmune diseases. The company operates as a target discovery platform with a pipeline of first-in-class immunotherapy candidates.
BiotechHealthtech
Investors · 5
In the news
- Case Study: Georgiamune - Karbokarbocom.com · 2024
- Georgiamune Expands Cancer Treatment Pipeline with Two Novel Drugs Within Five Months of Launchfinance.yahoo.com · 2024
- The Week’s 10 Biggest Funding Rounds: Neuralink Connects With $280M, Biotech Goes Big Againnews.crunchbase.com · 2023
- Georgiamune 8/9/2023 Capital Raise - Gaebler.com Venture Capital Databasegaebler.com